Search

Your search keyword '"Endlicher, E."' showing total 216 results
Start Over Author "Endlicher, E."
216 results on '"Endlicher, E."'

22. Fluorescence endoscopy for the detection of low and high grade dysplasia in ulcerative colitis using systemic or local 5-aminolaevulinic acid sensitisation. (Inflammatory Bowel Disease)

Author

Messmann, H., Endlicher, E., Freunek, G., Rummele, P., Scholmerich, J., and Knuchel, R.

Subjects
Diagnosis, Complications and side effects, Usage, Prognosis, Methods, Dysplasia -- Diagnosis -- Prognosis -- Complications and side effects, Ulcerative colitis -- Prognosis -- Complications and side effects -- Diagnosis, Endoscopy -- Methods -- Usage
Abstract

Background and aims: Longstanding ulcerative colitis (UC), especially in the presence of epithelial dysplasia, is associated with an increased risk of developing cancer. As dysplasia is not visible during routine [...]

Published
2003

32. Hypoxia Induces the Expression of Transketolase-Like 1 in Human Colorectal Cancer

Author

Bentz S., Cee A., Endlicher E., Wojtal K. A., Naami A., Pesch T., Lang S., Schubert P., Fried M., Weber A., Coy J. F., Goelder S., Knüchel R., Hausmann M., Rogler G., University of Zurich, and Cee, A

Subjects
Adult, Male, medicine.medical_specialty, Blotting, Western, 610 Medizin, 610 Medicine & health, Biology, Real-Time Polymerase Chain Reaction, 03 medical and health sciences, 0302 clinical medicine, Downregulation and upregulation, 10049 Institute of Pathology and Molecular Pathology, Cell Line, Tumor, Internal medicine, medicine, Humans, 2715 Gastroenterology, RNA, Messenger, Hypoxia, Aged, 030304 developmental biology, Aged, 80 and over, Regulation of gene expression, ddc:610, 0303 health sciences, Messenger RNA, Gastroenterology, Middle Aged, Immunohistochemistry, digestive system diseases, Up-Regulation, 3. Good health, Gene Expression Regulation, Neoplastic, Blot, 10219 Clinic for Gastroenterology and Hepatology, Real-time polymerase chain reaction, Endocrinology, Anaerobic glycolysis, Cell culture, 030220 oncology & carcinogenesis, Cancer research, Female, Transketolase, Colorectal Neoplasms, Glycolysis, HT29 Cells
Abstract

Background and Aims: Transketolase-like (TKTL) 1 is one of the key enzymes for anaerobic sugar degradation even in the presence of oxygen (aerobic glycolysis). Transketolase-dependent reactions supply malignant tumors with ribose and NADPH. Therefore, TKTL1 activity could be crucial for tumor proliferation and survival. The aim of the study was to evaluate the expression of TKTL1 in colorectal cancer (CRC) and its regulation under hypoxic conditions. Methods: We studied TKTL1 mRNA and protein expression in CRC cell lines and human CRC biopsies by quantitative real-time PCR, Western blotting and immunohistochemistry. Regulation of TKTL1 under oxygen depletion was analyzed by cultivating cells either in a three-dimensional spheroid model or in a hypoxia incubator chamber. Results: TKTL1 mRNA was heterogeneously expressed in monolayers of cells with high levels in HT-29 and SW480. TKTL1 protein was also clearly detectable in HT-29 and SW480. Hypoxia-inducible factor (HIF)-1α protein expression correlated with TKTL1 protein expression in SW480 spheroids over time. On the one hand, induction of hypoxia in T84 spheroids did not induce TKTL1; on the other hand, hypoxia by incubation at 1% O2 in a hypoxia incubator chamber clearly showed an upregulation of TKTL1. In 50% of CRC patients, TKTL1 protein expression was upregulated in tumor compared to non-tumor tissue. The immunohistochemical staining of TKTL1 in CRC patient samples resulted in 14 positive and 30 negative samples. Conclusions: TKTL1 expression correlated with HIF-1α protein expression and was induced upon hypoxic conditions which could facilitate energy supply to tumors under these circumstances.

Published
2013
Full Text
View/download PDF

33. Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial

Author

Walter, I., primary, Schulz, U., additional, Vogelhuber, M., additional, Wiedmann, K., additional, Endlicher, E., additional, Klebl, F., additional, Andreesen, R., additional, Herr, W., additional, Ghibelli, L., additional, Hackl, C., additional, Wiest, R., additional, and Reichle, A., additional

Published
2017
Full Text
View/download PDF

36. Bleeding Jejunal Diverticulosis in a Patient with Myasthenia Gravis

Author

Zuber-Jerger, I., Endlicher, E., and Kullmann, F.

Subjects
Article Subject, digestive system, digestive system diseases
Abstract

A seventy-year-old male presented with severe myasthenia gravis and an episode of obscure bleeding. There was a history of gastric ulcer leading to Billroth II surgery twenty-five years ago. Upper endoscopy revealed no pathology. Colonoscopy showed a few solitary diverticula and traces of old blood in the terminal ileum. Capsule endoscopy pictured red smear in the upper jejunum. Diverticula were seen as well. Suspecting bleeding jejunal diverticulosis double balloon enteroscopy was performed. The complete jejunal ascending loop and about 100 cm of the jejunum through the descending jejunal loop could be inspected. Large diverticula with fecoliths were found in both loops. Bleeding had ceased. The patient was discharged to neurology for optimizing therapy for myasthenia gravis.

Published
2008
Full Text
View/download PDF

37. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

Author

Lordick, F, Luber, B, Lorenzen, S, Hegewisch-Becker, S, Folprecht, G, Wöll, E, Decker, T, Endlicher, E, Röthling, N, Schuster, T, Keller, G, Fend, F, Peschel, C, Lordick, F, Luber, B, Lorenzen, S, Hegewisch-Becker, S, Folprecht, G, Wöll, E, Decker, T, Endlicher, E, Röthling, N, Schuster, T, Keller, G, Fend, F, and Peschel, C

Abstract

BACKGROUND: Cetuximab enhances the efficacy of chemotherapy in several cancer types. This trial assessed the activity of cetuximab and chemotherapy in advanced gastric cancer. METHODS: Patients with previously untreated, metastatic, gastric cancer received cetuximab 400 mg m(-2) at first infusion followed by weekly infusions of 250 mg m(-2) combined with FUFOX (oxaliplatin 50 mg m(-2), 5-FU 2000 mg m(-2), and DL-folinic acid 200 mg m(-2) d1, 8, 15 and 22 qd36). The primary endpoint was tumour response. RESULTS: Overall, 52 patients were enrolled. The most common grade 3/4 toxicities were diarrhoea (33%), and skin toxicity (24%). Efficacy was evaluable in 46 patients who showed a response rate of 65% (CI 95%: 50-79%) including four complete responses. Time to progression (TTP) was 7.6 months (CI 95%: 5.0-10.1 months) and overall survival (OS) was 9.5 months (CI 95%: 7.9-11.1 months). Epidermal growth factor receptor (EGFR) was detectable in 60% of tumours but showed no correlation with treatment outcome. A KRAS mutation was found in only 1 of 32 (3%) tumour samples analysed. CONCLUSION: Cetuximab plus FUFOX showed an interesting high response rate in metastatic gastric cancer. Cetuximab plus platinum-fluoropyrimidine chemotherapy is at present being investigated in a phase III randomised controlled trial.

Published
2010

38. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer

Author

Harder, J, primary, Ihorst, G, additional, Heinemann, V, additional, Hofheinz, R, additional, Moehler, M, additional, Buechler, P, additional, Kloeppel, G, additional, Röcken, C, additional, Bitzer, M, additional, Boeck, S, additional, Endlicher, E, additional, Reinacher-Schick, A, additional, Schmoor, C, additional, and Geissler, M, additional

Published
2012
Full Text
View/download PDF

42. Phase I/II study with trabedersen (AP 12009) monotherapy for the treatment of patients with advanced pancreatic cancer, malignant melanoma, and colorectal carcinoma.

Author

Oettle, H., primary, Hilbig, A., additional, Seufferlein, T., additional, Tsianakas, A., additional, Luger, T., additional, Schmid, R. M., additional, von Wichert, G., additional, Endlicher, E., additional, Garbe, C., additional, Kaehler, K. K., additional, Hauschild, A., additional, Enk, A., additional, Kiessling, P., additional, Schmaus, S., additional, Heinrichs, H., additional, and Schlingensiepen, K., additional

Published
2011
Full Text
View/download PDF

44. KRAS Mutation in Metastatic Pancreatic Ductal Adenocarcinoma: Results of a Multicenter Phase II Study Evaluating Efficacy of Cetuximab plus Gemcitabine/Oxaliplatin (GEMOXCET) in First-Line Therapy

Author

Kullmann, F., primary, Hartmann, A., additional, Stöhr, R., additional, Messmann, H., additional, Dollinger, M.M., additional, Trojan, J., additional, Fuchs, M., additional, Hollerbach, S., additional, Harder, J., additional, Troppmann, M., additional, Kutscheidt, A., additional, and Endlicher, E., additional

Published
2011
Full Text
View/download PDF

49. Cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric cancer: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

Author

Lordick, F, primary, Luber, B, additional, Lorenzen, S, additional, Hegewisch-Becker, S, additional, Folprecht, G, additional, Wöll, E, additional, Decker, T, additional, Endlicher, E, additional, Röthling, N, additional, Schuster, T, additional, Keller, G, additional, Fend, F, additional, and Peschel, C, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results